Manchester Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Manchester Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q1	–	Sell	-70	Closed	-$346K	–	932
2014 Q4	$346K	Hold	70	–	–	0.04%	233
2014 Q3	$286K	Buy	70 +19	+37%	+$71.3K	0.04%	257
2014 Q2	$205K	Hold	51	–	–	0.03%	359
2014 Q1	$231K	Buy	+51	New	+$206K	0.04%	304
2013 Q4	–	Sell	-54	Closed	-$222K	–	970
2013 Q3	$222K	Hold	54	–	–	0.04%	304
2013 Q2	$212K	Buy	+54	New	+$222K	0.04%	293

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

EAM

Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

OIM

Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

Manchester Capital Management's ACOR Position: Q1 2015 in Review

Manchester Capital Management sold out of Acorda Therapeutics (ACOR) in Q1 2015, closing a stake of 70 shares — an estimated $346K sold.

Manchester Capital Management first reported a position in ACOR in Q2 2013 and held it in 6 quarters. The position peaked at $346K in Q4 2014. 190 funds tracked by Wall St. Rank hold ACOR as of Q1 2015.

Manchester Capital Management reported no remaining Acorda Therapeutics position as of Q1 2015 after selling out during the quarter.
Manchester Capital Management sold 70 Acorda Therapeutics shares in Q1 2015, an estimated $346K.
Manchester Capital Management first reported a position in Acorda Therapeutics in Q2 2013 and held it in 6 quarters.
Manchester Capital Management's Acorda Therapeutics position peaked at $346K in Q4 2014.
190 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q1 2015.

Based on Manchester Capital Management's 13F filing for Q1 2015, filed 7 May 2015.